Address for correspondence: Tomasz Iwanowski, Dermedica, Gdansk, Poland, phone: +48 501 926 907, e-mail: tomasziwan@gmail.com Received: 3.07.2020, accepted: 12.08.2020.
Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality
of life instrument (VitiQoL) into Polish
Tomasz Iwanowski1, Piotr Szlązak1, Monika Zabłotna2, Berenika Olszewska2, Małgorzata Sokołowska-Wojdyło2
1Dermedica, Gdansk, Poland
2Department of Dermatology, Venerology and Allergology, Medical University of Gdansk, Gdansk, Poland
Adv Dermatol Allergol 2021; XXXVIII (4): 636–643 DOI: https://doi.org/10.5114/ada.2021.108896
A b s t r a c t
Introduction: Vitiligo is an acquired chronic depigmenting disorder of the skin, predominantly asymptomatic. Al- though vitiligo does not cause direct physical impairment, it is commonly believed that it can produce an important psychosocial burden.
Aim: To translate, cross-culturally adapt and validate the vitiligo-specific health-related quality of life instrument (VitiQoL) into Polish.
Material and methods: The study was conducted online on 97 patients with vitiligo from our private outpatient departments in Gdynia and Gdansk, Poland from May 2018 to December 2019.
Results: There was a significant correlation between VitiQoL and DLQI (r = 0.90, p < 0.001) and also between VitiQoL-PL and subjects’ assessment of the severity of their disease (r = 0.94, p < 0.001). We also found a good correlation between the total DLQI and subjects’ assessment of the severity of their disease (r = 0.87, p < 0.001).
Conclusions: The physicians treating this disease still do not have a specific instrument for assessing patients’ QoL in Poland. They have to administer other non-vitiligo specific questionnaires to do so. A Polish version of a specific index for estimating quality of life of patients with vitiligo was validated and implemented through an online survey.
Key words: indicators of quality of life, quality of life, vitiligo.
Introduction
Vitiligo is an acquired chronic depigmenting disorder of the skin, predominantly asymptomatic, characterized by amelanotic macules and patches that affects 0.5% to 2% of the world’s population [1]. Its prevalence is not re- lated to age or ethnicity, more than half of cases occur before the age of 20 years and 95% of all cases are under the age of 40 [2–5]. The cause of the disease is uncertain but seems to be dependent on the interaction of genetic, immunological and neurogenic factors [6, 7]. Although vitiligo does not cause direct physical impairment, it is commonly believed that it can produce a significant psychosocial burden [8]. Numerous studies have dem- onstrated a varying form of stigmatization, defined as a process in which skin appearance is negatively judged and persons who are affected experience absence of acceptance because of their visible symptoms. Patients
experience distress and anxiety, are often glared at or even avoided in fear of infection or disgust. Patients have various degrees of emotional disturbances, includ- ing low mood, loss of pleasure, poor body image, poor self-care, low self-esteem, and high stress [9, 10]. Other authors show that many vitiligo patients feel distressed and stigmatized by their condition, especially in relation to social activities [11]. It is also believed that exposing the body causes anxiety and embarrassment, which in more intimate encounters may have a negative effect on sexual relationships [12]. In other words, there appears to be an impact of vitiligo on the overall patient quality of life (QoL) [13]. Nevertheless, vitiligo is often regarded as a cosmetic issue, and impairment of QoL tends to be underestimated [14].
A disease-specific questionnaire for vitiligo has been developed and validated in the English language: the vitiligo-specific quality of life instrument (VitiQoL) [5].
The VitiQoL is a questionnaire of 15 items, with item scores from 0 (never) to 6 (all the time). It yields a total score from 0 to 90. Question 16 of the VitiQoL question- naire is a self-reported severity scale ranging from 0 (no skin involvement) to 6 (most severe case). The question- naire proved to be a promising clinical and epidemio- logical study instrument, and a powerful marker of the treatment outcome. An exploratory factor analysis with oblique rotation yielded 3 factors: participation limita- tion, stigma, and behaviour. The instrument was trans- lated, culturally adapted and validated into Brazilian Por- tuguese (VitiQoL-PB) [15] and Iranian [16].
Aim
The aim of this study was to perform the translation, cross-cultural adaptation and validation of the VitiQoL into Polish (VitiQoL-PL). What is more, we are the first to use it through an online survey.
Material and methods
Two bilingual physicians translated the English ver- sion of the VitiQoL questionnaire to Polish, then the Polish version was translated to English by other two bilingual dermatologists who had not read the original questionnaire (back to back translation). Afterwards, the final version was compared with the original English ver-
sion. The authors of the VitiQoL questionnaire authorized its translation and cross-cultural adaptation.
The study was conducted online on 97 patients with vitiligo from our private outpatient departments in Gdynia and Gdansk, Poland from May 2018 to De- cember 2019. Based on the original study and the WHO recommendations for the development of quality of life questionnaires, a specific questionnaire on demographic data, the VitiQoL questionnaire (Table 1) and a generic instrument for dermatological diseases, the DLQI (Der- matology Life Quality Index) (Table 2), were administered to 97 subjects. The VitiQoL questionnaire consisted of 15 questions with a seven-point Likert scale (0–6). The final scores could range from 0 to 90, in which patients with higher scores showed poorer quality of life.
In addition, subjects made a personal assessment of their severity of vitiligo, using a scale ranging from 0 (no skin involvement) to 6 (most severe cases), which cor- responded to question 16 of the VitiQoL questionnaire.
Patients were enrolled based on their consent and data were analyzed with respect to their confidentiality.
Statistical analysis
The qualitative features were analyzed using the χ2 test using the Pearson method. Independent quantita- tive variables meeting the assumptions for parametric tests were analyzed using the Student’s test. Quantita- tive variables that did not meet the assumptions of para- Table 1. VitiQoL questionnaire
The aim of these questions is to measure how much your skin has affected you over past month.
During the past month (0 – Not at all, 6 – All of the time):
Have you been bothered by the appearance of your skin condition? 0 1 2 3 4 5 6
Have you felt frustrated about your skin condition? 0 1 2 3 4 5 6
Has your skin condition made it hard to show affection? 0 1 2 3 4 5 6
Has your skin condition affected your daily activities? 0 1 2 3 4 5 6
When you were talking to someone, have you worried about what they may be thinking of you? 0 1 2 3 4 5 6
Have you been afraid that people will find fault with you? 0 1 2 3 4 5 6
Have you felt embarrassed or self-conscious because of your skin? 0 1 2 3 4 5 6
Has your skin condition influenced the clothes you wear? 0 1 2 3 4 5 6
Has your skin condition affected your social or leisure activities? 0 1 2 3 4 5 6
Has your skin condition affected your emotional well-being? 0 1 2 3 4 5 6
Has your skin condition affected your overall physical health? 0 1 2 3 4 5 6
Has your skin condition affected your grooming practices (i.e. hairstyle, use of cosmetics)? 0 1 2 3 4 5 6 Has your skin condition affected your sun protection efforts during recreation (i.e. limiting exposure
time during peak sun hours, seeking shade, wearing hat, long sleeves or pants)?
0 1 2 3 4 5 6
Has your skin condition affected your chances for making new friends? 0 1 2 3 4 5 6
Have you worried about progression or spread of disease to new areas of the body? 0 1 2 3 4 5 6 Please check how severe you currently feel your skin condition is (0 - No skin involvement, 6 – Most
severe case):
Severity of skin condition?
0 1 2 3 4 5 6
Table 2. DLQI questionnaire DERMATOLOGY LIFE QUALITY INDEX
The aim of this questionnaire is to measure how much your skin problem has affected your life over the last week. Please tick one box for each question.
Over the last week, how itchy, sore, painful or stinging has your skin been?
Very much A lot A little Not at all Over the last week, how
embarrassed or self conscious have you been because of your skin?
Very much A lot A little Not at all Over the last week, how
much has your skin interfered with you going shopping or looking after your home or garden?
Very much A lot A little Not at all
Not relevant
Over the last week, how much has your skin influenced the clothes you wear?
Very much A lot A little Not at all
Not relevant
Over the last week, how much has your skin affected any social or leisure activities?
Very much A lot A little Not at all
Not relevant
Over the last week, how much has your skin made it difficult for you to do any sport?
Very much A lot A little Not at all
Not relevant
Over the last week, has your skin prevented you from working or studying?
If “No”, over the last week how much has your skin been a problem at work or studying?
Yes No
A lot A little Not at all
Not relevant
Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives?
Very much A lot A little Not at all
Not relevant
Over the last week, how much has your skin caused any sexual difficulties?
Very much A lot A little Not at all
Not relevant
Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time?
Very much A lot A little Not at all
Not relevant
Please check you have answered EVERY question. Thank you.
metric tests were analyzed using non-parametric tests:
the Mann-Whitney U test or the Kruskal-Wallis test.
Spearman’s correlation coefficient was used to describe the correlation strength of two features (VitiQoL-PB and DLQI). In all tests, p < 0.05 was considered to be a sig- nificant level of statistical significance. Statistical calcula- tions were made using Statistica, version 12.0. (StatSoft, Inc. 2015). Additionally, the Cronbach’s α coefficient was used to check the reliability of the VitiQoL-PB question- naire.
Results
The questionnaire was completed by 97 patients.
Their demographic and clinical characteristics are de- scribed in Table 3. The average VitiQoL-PL score was 39.65 ±23.34; while the median DLQI was 4.0 (inter- quartile range P25 = 2 and P75 = 10). Overall, women had poorer QoL (higher VitiQoL scores) than men, 49.79
±21.50 and 27.45 ±19.45, respectively. The educational level had no impact on the VitiQoL result (p = 0.43). In our group, Singles scored: 55.07 ±21.93, folloved by Di- vorced/Separated: at 47.66 ±21.66, and Widowed: at 27.00 ±19.67. In our study, the impact of previous/on- going therapy was significant (p = 0.008). Patients that were previously treated for vitiligo got VitiQoL medium scores at 46.32 ±19.15 and a group without any treatment prior to current scored 34.98 ±24.99. The patients that were treated with phototherapy scored higher at 48.44
±18.64 than the group of patients that never had such a treatment at 37.65 ±23.93. The single item that most contributed to the VitiQoL-PL score was related to feeling bothered by the appearance of the skin (question 1). Oth- er items that significantly contributed to the final score were: feeling frustration about the skin condition (ques- tion 2), embarrassment or inhibition because of the skin (question 7) and social or leisure activities (question 9).
We have also found a strong correlation between gender and QoL in the DLQI results: women showed higher results: 8.15 ±5.32 compared to 3.79 ±4.03 in men. DLQI scores in certain martial status groups looked similar to VitiQoL, with Singles reaching 10.28 ±5.83, Divorced/ Separated at 7.16 ±4.76 and Married with the lowest result at 3.54 ±3.10. The impact of previous/
ongoing therapy on VitiQoL was statistically significant (p = 0.015). Previously treated patients got higher scores (7.17±4.81 to 5.47±5.44) but this time treatment method had no impact on the final score.
There was a significant correlation between VitiQoL and DLQI (r = 0.90, p < 0.001) (Figure 1) and also be- tween VitiQoL-PL and subjects’ assessment of the sever- ity of their disease (r = 0.94, p < 0.001) (Figure 2). We also found a good correlation between the total DLQI and subjects’ assessment of the severity of their disease (r = 0.87, p < 0.001) (Figure 3).
Table 3. Demographic and clinical characteristic of our patients
Parameter Phototherapy Other treatment Total
Median (min.–max.)
Duration of the disease 16.28 (2.00-42.00) 13.11 (2.00-34.00) 13.70 (2.00-42.00)
Parameter N (%)
Gender:
Female 14 (77.78) 39 (49.37) 53 (54.64)
Male 4 (22.22) 40 (50.63) 44 (45.36)
Educational level:
Complete primary education 0 (0) 6 (7.59) 6 (6.19)
Incomplete secondary education 0 (0) 1 (1.27) 1 (1.03)
Complete secondary education 0 (0) 28 (35.44) 28 (28.87)
Incomplete higher education 0 (0) 11 (13.92) 11 (11.34)
Complete higher education 18 (100) 33 (41.77) 51 (52.58)
Marital status:
Married 7 (38.89) 41 (51.90) 48 (49.48)
Divorced/separated 4 (22.22) 14 (17.72) 18 (18.56)
Widowed 2 (11.11) 1 (1.27) 3 (3.09)
Single 5 (27.78) 23 (29.11) 28 (28.87)
Total 18 (18.56) 79 (81.44) 97
Figure 1. Correlation between VitiQoL-PB and DLQI
DLQI
–20 0 20 40 60 80 100 120 0 20 40
VitiQoL-PB 0.95 CI
40
20
0 25
20
15
10
5
0
–5
Figure 2. Correlation between VitiQoL-PB and question 16 of VitiQoL (self-reported severity of vitiligo)
Self-reported severity of vitiligoSelf-reported severity of vitiligo
–20 0 20 40 60 80 100 120 0 20 40
VitiQoL-PB 0.95 CI
–5 0 5 10 15 20 25 0 20 40
DLQI 0.95 CI
20
0 6
5
4
3
2
1
0
–1
40
20
0 6
5
4
3
2
1
0
–1
Table 4. Polish version of VitiQoL questionnaire
Celem poniższych pytań jest oszacowanie, w jakim stopniu stan Twojej skóry wpłynął na Twoje życie w ciągu ostatniego miesiąca.
W ciągu ostatniego miesiąca, w skali od 0 (nigdy/wcale/nie dotyczy) do 6 (bardzo):
Czy czułaś (czułeś) się skrępowana (skrępowany) z powodu wyglądu Twojej skóry? 0 1 2 3 4 5 6 Czy czułaś (czułeś) się sfrustrowana (sfrustrowany) z powodu stanu Twojej skóry? 0 1 2 3 4 5 6 Czy odczuwałaś (odczuwałeś) trudność w okazywaniu uczuć z powodu stanu Twojej skóry? 0 1 2 3 4 5 6
Czy stan Twojej skóry wpłynął na codzienne aktywności? 0 1 2 3 4 5 6
Czy podczas rozmowy z kimś martwiłaś (martwiłeś) się, co ta osoba o Tobie myśli? 0 1 2 3 4 5 6
Czy obawiałaś (obawiałeś) się, że ludzie będą Cię krytykować? 0 1 2 3 4 5 6
Czy czułaś (czułeś) się zażenowana (zażenowany) lub wycofana (wycofany) z powodu Twojej skóry? 0 1 2 3 4 5 6
Czy wygląd Twojej skóry wpłynął na dobór stroju? 0 1 2 3 4 5 6
Czy stan Twojej skóry wpłynął na Twoją aktywność społeczną i spędzany czas wolny? 0 1 2 3 4 5 6
Czy stan Twojej skóry wpłynął na Twój dobrostan emocjonalny? 0 1 2 3 4 5 6
Czy stan Twojej skóry wpłynął na Twoje ogólne zdrowie fizyczne? 0 1 2 3 4 5 6
Czy stan Twojej skóry wpłynął na to, jak dbasz o wygląd zewnętrzny (na przykład dobór fryzury lub używanie kosmetyków)?
0 1 2 3 4 5 6
Czy stan Twojej skóry wpłynął na to, jak dbasz o ochronę przeciwsłoneczną podczas aktywności fizycznej (na przykład ograniczenie ekspozycji na promienie słoneczne w godzinach największego nasłonecznienia, przebywanie w cieniu, noszenie nakrycia głowy, odzieży z długim rękawem i długimi nogawkami)?
0 1 2 3 4 5 6
Czy stan Twojej skóry wpłynął na szansę zawarcia nowych znajomości? 0 1 2 3 4 5 6
Czy martwiłaś (martwiłeś) się postępem i rozszerzaniem się choroby na inne okolice ciała? 0 1 2 3 4 5 6
Proszę oceń, jak poważny jest Twoim zdaniem stan Twojej skóry? 0 1 2 3 4 5 6
Figure 4. Correlation between DLQI and the disease duration
DLQI
–10 0 10 20 30 40 50 60 0 20 40
Disease duration [years] 0.95 CI
40
20
0 25
20
15
10
5
0
–5
Discussion
There are many disease-specific instruments for the evaluation of severity or QoL of a certain dermatosis, such as atopic dermatitis, acne and melasma. Until 2012 and the development of VitiQoL there were none specific to vitiligo. In Poland, physicians treating this disease still do not have a specific instrument for assessing patients QoL, and have to administer other non-vitiligo specific questionnaires to do so. In this study, the Polish version of a specific index for estimating quality of life of pa- tients with vitiligo was developed (Table 4).
Previously, the instrument was translated, culturally adapted and validated only into Brazilian Portuguese (VitiQoL-PB) [15] and Iranian [16]. In our study, VitiQoL total score was lower than in Portugal – 39.65±23.34, in comparison to 40.04+27.32 but higher than in Iran – 30.5±14.5. Similar to the Persian study, education had no impact on QoL which is a little unexpected, because pa- tients with a university education should be more aware of the nature of the problem and less worried about any potential consequences, and hence have better quality of life. This may be a result of gaining knowledge about the disease from other media like the internet which are becoming more impactful when it comes to patients self-studying. Female patients reported poorer QoL in all
4 studies, which was logically predictable, since all over the world, aesthetic issues are more considerable in women. This demonstrates a strong relationship be- tween gender and QoL and more attention should be paid to this group. Patients that were previously cured had higher VitiQoL-PL scores. Phototherapy treatment was statistically significant and the results showed that patients subjected to this kind of treatment had lower QoL. In contrast to the Iranian study, there was no as- sociation between VASI of exposed areas and quality of life. This was an unexpected discovery because we anticipated that patients with high VASI scores that are mainly cured with phototherapy would have higher Vi- tiQoL scores and thus lower QoL.
Regarding life quality and duration of the disease, the Persian group found that patients who had disease duration of 5 years or less and patients with 15–20 years of disease duration had better quality of life, although it was not statistically significant. In our study, there is a statistically significant negative correlation between DLQI, VitiQoL and disease duration. As the vitiligo contin- ues, the DLQI and VitiQoL values decrease (Figures 4, 5).
The VitiQoL-PL Cronbach’s α coefficient was similar to the coefficient of the original questionnaire and two other validations (our VitiQoL Cronbach’s α = 0.98, origi- Figure 5. Correlation between VitiQoL and the disease duration
VitiQoL-PB
–10 0 10 20 30 40 50 60 0 20 40
Disease duration [years] 0.95 CI
40
20
0 120
100
80
60
40
20
0
–20
nal = 0.935, Brazilian = 0.944, Persian = 0.956), which demonstrates the reliability of the instrument. Addition- ally, it showed a strong correlation with both the sub- jects’ assessment of disease severity and the DLQI. In the original VitiQoL, one of the limitations highlighted by the authors was the fact that the instrument should be validated and then used through the digital route of administration. We successfully managed to do so and have administered the questionnaire via an online sur- vey. We hope that from now on the impact of vitiligo on the quality of life in Poland can be assessed using a disease-specific questionnaire, which will contribute to a more complete and reliable evaluation of these pa- tients. Because of our work, physicians in Poland can now compare results of their studies of vitiligo and we all can correlate our work with international data.
Conflict of interest
The authors declare no conflict of interest.
References
1. Hann SK, Nordlund J. Vitiligo: a Monograph on Basic And Clinical Science. Blackwell Science, Oxford 2000.
2. Bolognia J, Jorizzo J, Schaffer J. Dermatology Text Book. 3rd ed. 2012; 1023-4.
3. Malhotra N, Dytoc M. The pathogenesis of vitiligo. J Cutan Med Surg 2013; 17: 153-72.
4. Patel AB, Kubba R, Kubba A. Clinicopathological correlation of acquired hypopigmentary disorders. Indian J Dermatol Venereol Leprol 2013; 79: 376-82.
5. Lilly E, Lu PD, Borovicka JH, et al. Development and valida- tion of a vitiligo-specific quality-of-life instrument (VitiQoL).
J Am Acad Dermatol 2013; 69: e11-8.
6. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo.
Lancet 2015; 386: 74-84.
7. Van Geel N, Speeckaert M, Brochez L, et al. Clinical profile of generalized vitiligo patients with associated autoimmune/
autoinflammatory diseases. J Eur Acad Dermatol Venereol 2014; 28: 741-6.
8. Porter JR, Beuf AH, Nordlund JJ, Lerner AB. Psychological re- action to chronic skin disorders. A study of patients with vitiligo. Gen Hosp Psychiatry 1979; 1: 73-7.
9. Kent G, Al-Abadie M. Factors affecting responses on Derma- tology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol 1996; 21: 330-3.
10. Porter JR, Beuf HA, Lerner AB, Nordlund JJ. Psychosocial ef- fect of vitiligo: a comparison of vitiligo patients with normal subjects, with psoriasis patients with other pigmentary dis- orders. J Am Acad Dermatol 1986; 15: 220-4.
11. Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes 2003; 1: 58.
12. Porter JR, Beuf AH, Lerner AB, Nordlund JJ. The effect of vit- iligo on sexual relationships. J Am Acad Dermatol 1990; 22:
221-2.
13. Ongenae K, van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005; 152: 1165-72.
14. Ezzedine K, Sheth V, Rodrigues M, et al. Vitiligo is not a cos- metic disease. J Am Acad Dermatol 2015; 73: 883-5.
15. Boza JC, Kundu RV, Fabbrin A, et al. Translation, cross-cultur- al adaptation and validation of the vitiligospecific health- related quality of life instrument (VitiQoL) into Brazilian Portuguese. An Bras Dermatol 2015; 90: 358-62.
16. Hedayat K, Karbakhsh M, Ghiasi M, et al. Quality of life in patients with vitiligo: a cross-sectional study based on Vit- iligo Quality of Life index (VitiQoL). Health Qual Life Out- comes 2016; 14: 86.
